Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAP polypill trial for cardiovascular disease prevention
ACTRN12608000584336Phase 3Terminated
- Sponsor
- The George Institute for Global Health
- Start
- Apr 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin, simvastatin, lisinopril, atenolol and hydrochlorothiazide in cardiac morbidity (2 arms), sponsored by The George Institute for Global Health. Primary endpoints: Adherence to preventive cardiovascular medicines, Change in blood pressure and 1 more. Started Apr 2009; status: terminated.
02
Drugs
aspirinsimvastatinlisinoprilatenololhydrochlorothiazide
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on ACTRN12608000584336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000584336.